Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | HSPA1A | P0DMV8 | 4/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245088 | 0.76 | HSPA1A (0.49) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL10924726 | 0.76 | PTPN7 (0.52) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL1877920 | 0.76 | PTPN7 (0.49) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL9656639 | 0.72 | CYSLTR1 (0.38) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7892118 | 0.71 | PTPN7 (0.53) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL12203527 | 0.70 | KMT2A (0.61) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL10877400 | 0.70 | HSPA1A (0.49) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL1200754 | 0.70 | HSPA1A (0.43) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL832933 | 0.69 | PTPN7 (0.54) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL5473253 | 0.67 | HSPA1A (0.40) | MAPTMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1902026-B1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | LILLY CO ELI (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| EP-1802300-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-1902026-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1802300-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007002181-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006044232-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNH2, KCNN1, KCNH3 | MAPT 1396/4885MEN1 992/4885KMT2A 2911/4885 |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | MAPT 2148/4885MEN1 3684/4885KMT2A 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.